CAJ | 학술논문

目的：观察妊娠期高血压疾病（HDCP）患者与健康非孕妇及健康晚期孕妇的同型半胱氨酸（Hcy）、D-二聚体（D-D）及超敏 C 反应蛋白（hs-CRP）水平的变化，探讨其相关性。方法选择了 HDCP 患者80例，其中妊娠期高血压38例，子痫前期轻度26例，子痫前期重度16例；并随机选取同期健康晚期孕妇36例，健康非孕妇30例作对照，分别用循环酶法测定 Hcy，用乳胶免疫比浊法测定 D-D，用免疫比浊法测定 hs-CRP 水平。结果与健康非孕妇组及健康晚期孕妇组比较，HDCP 组 Hcy、D-D 及hs-CRP 水平均显著升高，并随病情加重而呈升高趋势，差异有统计学意义（P ＜0.01）。结论在妊娠期，及时监测患者 Hcy、D-D、hs-CRP 水平，可进行有效的不良妊娠预测，从而及时采取药物干预、通过临床来纠正 HDCP 患者病情的发生、发展，为临床评价病情变化及预后提供了有意义的参考指标。
목적：관찰임신기고혈압질병（HDCP）환자여건강비잉부급건강만기잉부적동형반광안산（Hcy）、D-이취체（D-D）급초민 C 반응단백（hs-CRP）수평적변화，탐토기상관성。방법선택료 HDCP 환자80례，기중임신기고혈압38례，자간전기경도26례，자간전기중도16례；병수궤선취동기건강만기잉부36례，건강비잉부30례작대조，분별용순배매법측정 Hcy，용유효면역비탁법측정 D-D，용면역비탁법측정 hs-CRP 수평。결과여건강비잉부조급건강만기잉부조비교，HDCP 조 Hcy、D-D 급hs-CRP 수평균현저승고，병수병정가중이정승고추세，차이유통계학의의（P ＜0.01）。결론재임신기，급시감측환자 Hcy、D-D、hs-CRP 수평，가진행유효적불량임신예측，종이급시채취약물간예、통과림상래규정 HDCP 환자병정적발생、발전，위림상평개병정변화급예후제공료유의의적삼고지표。
Objective To investigate the relationship between hypertensive disorder complicating pregnancy(HDCP)with homo-cysteine,D-D and high sensitive C-reactive protein(hs-CRP).Methods 80 HDCP women included 38 cases of gestational hyperten-sion,26 cases of mild preeclampsia and 16 cases of severe preeclampsias,and at the same time 36 normal late-term pregnant women and 30 non-pregnant normal women were selected as the control group.The plasma Hcy was determined by the enzymatic cycling assay,D-D was determined by the latex immune turbidimetry and hs-CRP was determined by the nephelometry immuno assay,re-spectively.Results The plasma Hcy,D-D and hs-CRP levels in the HDCP group were significantly increased compared with the normal non-pregnancy women group and the normal late-term pregnancy women group controls and showed the increasing trend with the aggravation of disease condition,the differences had the statistical significance(P <0.01).Conclusion Timely monitoring the plasma Hcy,D-D and hs-CRP levels can effective conduct the adverse pregnancy prediction,thus timely takes the medication in-tervention for correcting the occurrence and development of the disease condition,and provides the significant reference indexes for evaluating the change and prognosis of the disease condition in clinic.